Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (7987)	6/5/1998 1:07:00 AM
From: John Metcalf	Read Replies (4) \| Respond to of 9262

{A Tri} TTNP on the ascending triangle list is a small biotech ($65mm mkt cap) that has held up well in the recent bio-slide. It popped modestly on news of presentation of three studies of cancer vaccines. More important is Iloperidone, a drug for schizophrenia for which Novartis is paying development costs, now in Phase III clinical trials. Though the outcome is uncertain, Novartis would like to replace its own Clozaril with Iloperidone because Clozaril can cause a rare but sometimes fatal side effect and requires weekly lab work (in the US; in Europe, lab frequency is less).